Merck KGaA lung cancer vaccine to re-enter Phase III – FierceVaccines

by lowes1 on September 26, 2013

Merck KGaA lung cancer vaccine to re-enter Phase III
FierceVaccines
When Merck KGaA's lung cancer vaccine Stimuvax flunked Phase III trials in December, many thought the project was dead. Merck continued to work on the compound though, and now, having probed the improvements seen in some patients in the last trial, 
Merck Serono puts faith in lung cancer candidatePMLiVE

all 2 news articles »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: